Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Abivax

Market Cap 6.78B 7.86B 6.24B 5.85B 10.99B 743B 11.1B 73.75B 28.81B 364B 29.51B 28.89B 1,259B P/E Ratio 2026 *
-22.1x
P/E Ratio 2027 * -24.6x
Enterprise Value 6.29B 7.3B 5.79B 5.43B 10.21B 690B 10.31B 68.48B 26.75B 338B 27.4B 26.82B 1,169B EV / Sales 2026 *
1,677x
EV / Sales 2027 * 69.9x
Free-Float
92.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.06%
1 week-4.54%
Current month-24.96%
1 month-14.08%
3 months-20.62%
6 months-18.33%
Current year-29.32%
1 week 80.7
Extreme 80.7
90.45
1 month 60.45
Extreme 60.45
118.6
Current year 60.45
Extreme 60.45
132
1 year 5.12
Extreme 5.12
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
Manager TitleAgeSince
Chief Executive Officer 68 05/05/2023
Director of Finance/CFO - 02/01/2017
Chief Tech/Sci/R&D Officer - 19/03/2026
Director TitleAgeSince
Chairman - 16/08/2022
Chairman 68 05/05/2023
Director/Board Member 60 11/07/2023
Date Insider Type Main position Quantity % Market Cap.
05-21Fiscal year

Chief Executive Officer

35,456 0.0445%
03-23Fiscal year

Chief Executive Officer

35,456 0.0448%
02-20Free

Director

2,471 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-4.54%+1,392.98%+449.03% 7.85B
+0.96%+1.16%-12.70%-12.33% 43.03B
+3.71%+7.31%+300.68%+533.85% 32.71B
-1.83%-2.84%+12.08%-17.67% 30.29B
+0.41%-1.89%+0.47%+32.15% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.05%+8.40% - - 13.54B
-0.36%+1.76%+54.82%+111.22% 13.35B
-1.09%-2.31%+3.49%+5.00% 12.97B
+0.15%-0.29%+108.09%+75.89% 12.11B
Average +0.52%+0.43%+208.24%+133.25% 22.03B
Weighted average by Cap. +0.71%+0.68%+111.45%+115.53%

Financials

2026 *2027 *
Net sales 3.75M 4.35M 3.45M 3.24M 6.09M 412M 6.15M 40.84M 15.95M 202M 16.34M 16M 697M 90.09M 105M 82.92M 77.79M 146M 9.88B 148M 980M 383M 4.84B 392M 384M 16.74B
Net income -267M -310M -246M -230M -433M -29.26B -437M -2.9B -1.13B -14.33B -1.16B -1.14B -49.58B -215M -249M -198M -186M -349M -23.57B -352M -2.34B -914M -11.54B -936M -916M -39.94B
Net Debt -484M -562M -446M -418M -786M -53.12B -794M -5.27B -2.06B -26.01B -2.11B -2.06B -90.02B -483M -560M -444M -417M -783M -52.94B -791M -5.25B -2.05B -25.92B -2.1B -2.06B -89.7B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
15/06/26 85.10 +0.06% 219,130
12/06/26 85.05 -0.12% 116,959
11/06/26 85.15 +1.25% 195,790
10/06/26 84.10 -1.98% 196,939
09/06/26 85.80 -3.76% 280,592
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
85.05EUR
Average target price
115.77EUR
Spread / Average Target
+36.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!